Aromatase inhibitors are drugs that inhibit estrogen synthesis from androgens, so they can be used in FAT when there is residual estrogen secretion due to partial surgical removal, or as palliative treatment in advanced metastatic disease. This evidence concerns the gene CYP19A1 and metastatic neoplasm.